Plitidepsin vs Apratoxin A
Head-to-head comparison of Plitidepsin (Dehydrodidemnin B (Plitidepsin)) and Apratoxin A (Apratoxin A) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Plitidepsin | Apratoxin A |
|---|---|---|
| Category | Experimental | Experimental |
| Full Name | Dehydrodidemnin B (Plitidepsin) | Apratoxin A |
| Molecular Weight | 1110.3 Da | N/A |
| Half-Life | Approximately 44 hours | N/A |
| Amino Acids | N/A | N/A |
| Typical Dose | 1.5 mg/m2 IV | N/A in humans; nanomolar in vitro |
| Route | Intravenous | Intraperitoneal / Intravenous (preclinical) |
| Purity | ≥98% | ≥98% |
| Studies Count | 240 | 140 |
| Research Status | Clinical | Pre-clinical |
Plitidepsin Benefits
- ✓antineoplastic
- ✓antiviral
- ✓pro-apoptotic
- ✓anti-inflammatory
Apratoxin A Benefits
- ✓antineoplastic
- ✓anti-angiogenic
- ✓Sec61 inhibition
- ✓anti-proliferative
Plitidepsin Dosing
1.5 mg/m2 IV infusion in oncology trials|q21d or similar intermittent schedules|dose escalation and combination protocols in studies
Apratoxin A Dosing
preclinical in vitro nanomolar use|animal studies only|no human dosing established
Plitidepsin Side Effects
- ⚠nausea
- ⚠fatigue
- ⚠transaminase elevation
Apratoxin A Side Effects
- ⚠hepatotoxicity
- ⚠general cytotoxicity
- ⚠GI toxicity
Research Overview
Plitidepsin
Plitidepsin has been studied for its ability to disrupt eEF1A-dependent pathways, induce oxidative stress, and suppress tumor cell growth. It has reached clinical oncology development and was also evaluated as a candidate against SARS-CoV-2 in the literature.
Apratoxin A
Apratoxin A is a well-studied lead compound for targeting secretory and membrane protein biogenesis in cancer cells. Medicinal chemistry programs around apratoxins focus on improving selectivity and reducing hepatotoxicity while preserving potency.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.